Development and Invitro Characterization of Nanosponge Formulation of Lovastatin for Oral Delivery Using a Central Composite Design

DOI

10.2991/978-94-6463-813-4_12How to use a DOI?

Keywords

Nanosponges; Hypolipidemic agent; Eudragit-L100; zero-order release

Abstract

Nanosponges are new colloidal drug carriers with nanosized cavities to encapsulate both lipophilic and hydrophilic drug moieties. They can circumvent the various formulation challenges associated with poor water solubility, low bioavailability, targeting, and controlled release of actives. Lovastatin, a hypolipidemic drug encounters the major problems of poor water solubility and oral bioavailability. Hence the attempt was made to formulate and characterize lovastatin-loaded nanosponges. In this study, Eudragit L-100 was used as a polymer, Dichloromethane as a solvent, and PVA as a stabilizing agent to formulate lovastatin-loaded nanosponges. Different formulations with varying proportions of Eudragit L-100 and PVA were designed by using Design of experiments studies and nanosponges were prepared by the Emulsion solvent evaporation method. The FTIR spectra showed a stable character of lovastatin in a mixture of polymers and revealed the absence of drug-polymer interactions. The optimized formulation shows the average particle size of 251.6 nm, PDI was 0.428, the zeta potential was -22.7mv, percent entrapment efficiency was 95.18 ± 0.15 and CDR was 97.35 ± 0.19. Conclusions: The release kinetics of the improved formulation demonstrated zero-order drug release and were best suited to the Higuchi model, indicating that drug release occurs via diffusion.

Copyright

© 2025 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Jhansi Rani Mallam
AU  - Nagaraju Ravouru
PY  - 2025
DA  - 2025/08/13
TI  - Development and Invitro Characterization of Nanosponge Formulation of Lovastatin for Oral Delivery Using a Central Composite Design
BT  - Proceedings of the International symposium on Sustainable Drug Design and Nanoparticle development: Quantum and Computational Perspectives (SDDNDQCP 2025)
PB  - Atlantis Press
SP  - 165
EP  - 177
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-813-4_12
DO  - 10.2991/978-94-6463-813-4_12
ID  - Mallam2025
ER  -